Skip to content

Spatial Analysis of the Intestinal Microbiota in Healthy Subjects

Spatial Analysis of the Intestinal Microbiota in Healthy Subjects

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03918330
Enrollment
10
Registered
2019-04-17
Start date
2018-08-01
Completion date
2024-10-10
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Research on the human intestinal microbiota is common as there is rising evidence of its influence on host physiology and several diseases. Predominantly, it has been based on analyses of faecal samples because of their easy sampling. A minority of studies investigated the gut microbiota using mucosal samples. Not much is known about the spatial differences in microbiota composition along the large bowel. The spatial differences of the gut microbiota without preparation of the bowel have not been analysed yet. Furthermore, the composition of the microbiota of the luminal gut content has not been analysed yet. This study aims to gain knowledge of the microbial composition of luminal and mucosal samples at different segments of the lower gastrointestinal tract: ileum, caecum, ascending colon, transverse colon, descending colon, sigmoid colon and rectum, as well as of rectal swabs and faecal samples.

Detailed description

The investigators aim to evaluate complete colonoscopies from 10 healthy subjects. This study is used as a first explorative study of how the human gut microbiota is distributed along the lower gastrointestinal tract. No comparable studies in an uncleansed bowel have been performed so far. The number of subjects is based on other studies investigating the microbial composition of mucosal- and faecal-associated microbiota in which a sample size of 10 was enough to detect a difference. An equal number of men and women will be recruited. Drop-outs will be replaced.

Interventions

None listed

Sponsors

Region Örebro County
CollaboratorOTHER
Örebro University, Sweden
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Signed informed consent 2. Age: 18-65 years

Exclusion criteria

1. Known organic gastrointestinal disease (e.g. inflammatory bowel disease, irritable bowel syndrome, chronic diarrhoea or constipation) 2. History of or present gastrointestinal malignancy or polyposis 3. Recent (gastrointestinal) infection (within last 6 months) 4. History of major gastrointestinal surgery (e.g. gastric bypass) 5. Eosinophilic disorders of the gastrointestinal tract 6. Current communicable disease (e.g. upper respiratory tract infection) 7. Malignant disease and/or patients who are receiving systemic anti-neoplastic agents 8. Psychiatric diseases (e.g. dementia, depression, schizophrenia, autism, Asperger Syndrome) or other incapacity for adequate cooperation 9. Chronic neurological/neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis) 10. Autoimmune disease and/or patients receiving immunosuppressive medications 11. Major relevant allergies (e.g. food allergy, multiple allergies) 12. Chronic pain syndromes (e.g. fibromyalgia) 13. Chronic fatigue syndrome 14. Obesity (body mass index\>30) or metabolic syndrome 15. Antimicrobial treatment or prophylaxis within the last 3 months 16. Other chronic use of drugs that may affect the microbiome, e.g. proton pump inhibitors 17. Females who are pregnant or breast-feeding 18. Known clinically significant abnormal laboratory values 19. Abuse of alcohol or drugs 20. Probiotic intake within the last 6 weeks 21. Bowel cleansing within the last 6 months 22. Any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial

Design outcomes

Primary

MeasureTime frameDescription
Differences in the composition of the microbiota in luminal and mucosal samples along the large intestine Composition of the microbiota in luminal as well as mucosal samples1 day16S rRNA-based next generation sequencing

Secondary

MeasureTime frameDescription
Microbial composition of rectal and faecal microbiota1 day16S rRNA-based next generation sequencing
Metabolic profile in faecal samples along the intestinal tract1 daymetabolomics
Gene expression of transporters for bacterial products in mucosal biopsies along the colon1 day

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026